BioMarin Just Lit $270 Million on Fire

Sometimes the homework grades lie.

BMN 401 nailed the biological mechanism. PPi levels went up, which is exactly what the science said should happen. But biology is messy, and correcting one piece of a complex puzzle doesn't always fix the picture. Roughly half of all Phase 3 programs fail, according to broad industry analyses, and inadequate efficacy is the number one reason. About 57% of pivotal trial failures come down to the drug simply not working well enough in patients.

For rare diseases, the odds can be even tougher. These trials involve tiny patient populations, which makes it harder to demonstrate statistical significance, adding layers of complexity that can sink even well-designed programs.

The $270 Million Bet That Didn't Pay Off

BioMarin acquired Inozyme Pharma in mid-2025, paying $4.00 per share in an all-cash deal. At the time, BMN 401 was the crown jewel: a potential treatment for ENPP1 deficiency, ABCC6 deficiency, and end-stage kidney disease. Three shots on goal for $270 million seemed reasonable for a company that specializes in rare diseases.

Now all three shots have been pulled off the board.

Wall Street's reaction has been measured but not exactly cheerful. Guggenheim had already removed BMN 401 from its financial model after the mixed Phase 3 data surfaced earlier this year, calling success "highly unlikely." Stifel noted the failure creates "significant risk to approval" and removes an upside driver from the stock, even if BMN 401 wasn't central to the bull case. Leerink expressed skepticism about any regulatory path forward.

The saving grace? Analysts seem to agree this is painful but not fatal. The market had partly priced in the bad news, which may limit further downside from the formal discontinuation.

BioMarin Still Has Plenty of Cards to Play

Losing a $270 million asset stings, but BioMarin is hardly running on empty. The company's commercial portfolio includes nine marketed products, anchored by Voxzogo (for achondroplasia, a form of dwarfism) along with legacy franchises like Palynziq, Naglazyme, and Brineura.

The 2025 acquisition of Amicus Therapeutics for roughly $4.8 billion also brought in Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease), both already generating revenue.

On the pipeline side, BioMarin is pushing Voxzogo into new skeletal conditions including hypochondroplasia, and has BMN 333 (a long-acting candidate for achondroplasia), BMN 351 (a Phase 1/2 program in Duchenne muscular dystrophy), and BMN 820 (an oral therapy for a kidney condition called FSGS). There's depth here, even without BMN 401.

That said, the company dropped its previously stated $4 billion revenue target, which tells you the math has changed. Losing a pipeline asset doesn't just cost you the acquisition price; it costs you the future revenue you were counting on.

The Bigger Picture

BioMarin's stumble is a reminder that rare disease drug development is not the safe harbor it sometimes appears to be. Yes, rare disease drugs often get regulatory incentives, smaller trial requirements, and premium pricing. But the underlying science is just as unforgiving.

Phase 3 failure rates hover around 39% to 54% depending on how you slice the data. That means even after a drug survives years of preclinical work, Phase 1 safety testing, and Phase 2 dose-finding, it still faces something close to a coin flip at the finish line.

For BioMarin, the lesson is expensive but survivable. The company has a broad enough portfolio to absorb the hit, and its core franchise in Voxzogo continues to grow. But somewhere in a boardroom, someone is looking at a $270 million line item on the balance sheet and wondering what might have been.

In biotech, the graveyard of promising drugs is always accepting new residents. BMN 401 just got its plot.

When the FDA Commissioner Tries to Kill a Drug Himself

Reports claim FDA Commissioner Marty Makary personally tried to block KalVista's rare disease drug, an almost unprecedented intervention that raises uncomfortable questions about political influence at the agency. The drug got approved anyway, but the fallout is just beginning.